Key facts
- This page summarizes Diana M. Lanchoney's Form 4 filing for Diffusion Pharmaceuticals Inc. (CRVO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jul 2023, 17:30.
Diana M. Lanchoney - 30 Jun 2023 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)
- Reporting relationship
- Director
- Issuer ticker
- CRVO
- Reported as of
- 30 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jul 2023, 17:30:37 UTC
- Prior SEC filing
- 03 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ William R. Elder, attorney-in-fact for the Reporting Person
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Diana M. Lanchoney filed Form 4 for Diffusion Pharmaceuticals Inc. (CRVO) on 05 Jul 2023.
Change
- Previous filing in this sequence was filed on 03 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DFFN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +232
- Change %
- +158%
- Price
- Shares after
- 379
- Date
- 30 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
DFFN
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -85
- Change %
- -22%
- Price
- Shares after
- 294
- Date
- 30 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DFFN
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -232
- Change %
- -20%
- Price
- $0.000000
- Shares after
- 928
- Date
- 30 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 232
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer.